Outcomes of COVID-19 in patients with CLL: a multicenter international experienceAnthony R. Mato, José‐Ángel Hernández‐Rivas, Paul M. Barr et al.|Blood|2020Cited by 318
COVID-19 in patients with CLL: improved survival outcomes and update on management strategiesLindsey E. Roeker, Sigrid S. Skånland, Toby A. Eyre et al.|Blood|2021Cited by 70
Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimenMeghan C. Thompson, Anthony R. Mato, Rosemary Harrup et al.|Blood Advances|2022Cited by 57
Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective studyDavid Qualls, Gilles Salles, Nicholas Lambert et al.|Blood|2023Cited by 47
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignanciesMatthew S. Davids, Ian W. Flinn, Owen A. O’Connor et al.|Blood Advances|2021Cited by 21